JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Suletud

73.59 -1.31

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

73.52

Max

73.74

Põhinäitajad

By Trading Economics

Sissetulek

-923M

2.5B

Müük

1B

15B

P/E

Sektori keskmine

27.832

34.393

Dividenditootlus

2.12

Kasumimarginaal

16.947

Töötajad

94,300

EBITDA

-18M

5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+24.72% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.12%

2.54%

Turustatistika

By TradingEconomics

Turukapital

5.1B

231B

Eelmine avamishind

74.9

Eelmine sulgemishind

73.59

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

AstraZeneca PLC ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuli 2025, 08:08 UTC

Tulu

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29. juuli 2025, 06:46 UTC

Tulu

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8. aug 2025, 10:51 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1. aug 2025, 11:10 UTC

Kuumad aktsiad

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29. juuli 2025, 11:02 UTC

Tulu

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29. juuli 2025, 11:02 UTC

Tulu

AstraZeneca 2Q EPS $1.58 >AZN.LN

29. juuli 2025, 11:01 UTC

Tulu

AstraZeneca 2Q Rev $14.5B >AZN.LN

29. juuli 2025, 11:00 UTC

Tulu

AstraZeneca Results: H1 and Q2 2025

29. juuli 2025, 08:00 UTC

Market Talk
Tulu

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29. juuli 2025, 07:53 UTC

Market Talk
Tulu

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29. juuli 2025, 07:26 UTC

Market Talk
Tulu

AstraZeneca Shares Look Undervalued -- Market Talk

29. juuli 2025, 06:03 UTC

Tulu

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29. juuli 2025, 06:03 UTC

Tulu

AstraZeneca 2Q Total Revenue $14.46B

29. juuli 2025, 06:03 UTC

Tulu

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29. juuli 2025, 06:03 UTC

Tulu

AstraZeneca 2Q Core EPS $2.17

29. juuli 2025, 06:02 UTC

Tulu

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29. juuli 2025, 06:02 UTC

Tulu

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29. juuli 2025, 06:02 UTC

Tulu

AstraZeneca Backs 2025 View

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Rev $14.46B

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Adj EPS $2.17

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Pretax Pft $3.13B

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Net Pft $2.45B

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Oper Pft $3.51B

29. juuli 2025, 06:00 UTC

Tulu

AstraZeneca PLC 2Q EPS $1.57

28. juuli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22. juuli 2025, 10:19 UTC

Market Talk

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22. juuli 2025, 09:34 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9. juuli 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9. juuli 2025, 09:17 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28. mai 2025, 18:09 UTC

Tulu

Heart Disease Could Be a Goner When These New -2-

Võrdlus sarnastega

Hinnamuutus

AstraZeneca PLC ADR Prognoos

Hinnasiht

By TipRanks

24.72% tõus

12 kuu keskmine prognoos

Keskmine 93 USD  24.72%

Kõrge 97 USD

Madal 85 USD

Põhineb 4 Wall Streeti analüütiku instrumendi AstraZeneca PLC ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 69.55Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.